Intellia Withdraws from Hemophilia Collaboration with Regeneron

Intellia has exited a partnership with Regeneron to develop a factor IX gene editing therapy for hemophilia B, opting out of a deal that was signed in 2020. Despite this, Intellia remains eligible for up to $320 million in future milestones and still holds a 35% stake in a factor XIII insertion program for hemophilia A.